Insomnia: New Directions in Evaluation and Treatment

Scroll to the bottom of page to listen to the podcast

Program Overview:

Insomnia is a highly prevalent sleep disorder; it is sometimes observed as a primary disorder, but is often comorbid with other conditions. Whether as a primary or secondary condition, if left untreated, chronic insomnia can have a serious, detrimental impact on a person’s health, safety, and quality of life. Despite its prevalence and adverse effects, insomnia remains underdiagnosed and undertreated. Factors that contribute to the inadequate treatment of insomnia include the failure of patients to report the condition to clinicians, and clinician and patient misperceptions about the appropriate use and risks associated with hypnotic medications. This program will address effective strategies for diagnosing and treating patients with insomnia.

Learning Objectives

After completing this activity, the participant will be able to:

• Identify risk factors, determine appropriate screening tools, and accurately diagnose insomnia
• Evaluate current and emerging nonpharmacologic and pharmacologic therapies for acute and chronic insomnia on the basis of efficacy and safety and apply this knowledge/skill with patients

Accreditation/Designation Statement

Primary Care Network, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Primary Care Network designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience:
This activity is targeted to all physicians and other healthcare professionals who treat patients with insomnia.

Release Date: February 23, 2009
Expiration Date: February 23, 2010

Medium: Podcast

Acknowledgement of Commercial Support:

This activity was developed from the live Best Practices in Primary Care™ program held in San Antonio, Texas on May 30, 2008 which was funded by sanofi-aventis US.

Method of Participation:

To receive CME credit for this activity, you need to listen to the program. Upon finishing the podcast, complete the post-test and evaluation, and fill out all required personal information. To receive your CME certificate you will need to pass the post-test with 70% accuracy or better.

Post-test and Evaluation:

After completing this activity, click on the Post-test button at the end of the program. If you receive less than 70% on the post-test, you will be returned to the beginning of the activity to review the presentation again. Upon successful completion of the post-test, you will be asked to fill out a program evaluation form and prompted to print your CME certificate.

Statement of Disclosure and Dependence:

It is the policy of Primary Care Network, Inc. to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, Primary Care Network has Conflict of Interest and Disclosure Policies that are designed to ensure that Primary Care Network sponsored educational activities are fair balanced, independent, evidence-based and based on scientific rigor.

Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a Primary Care Network sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations at this Primary Care Education program are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.

Planning Committee and Disclosures

David N. Neubauer, MD (Chair)
Johns Hopkins Sleep Disorders Center
Baltimore, MD

Dr. Neubauer is a member of the speaker’s bureau for sanofi-aventis U.S. and Takeda Pharmaceuticals North America, Inc. He serves on the advisory board for Neurocrine Biosciences, Inc., sanofi-aventis, and Takeda.

Joseph Lieberman III, MD, MPH (Co-Chair)
Jefferson Medical College
Philadelphia, PA

Dr. Lieberman is a member of the speaker’s bureau for sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. He serves on the advisory board for sanofi-aventis, Takeda, and Wyeth.

Daniel N. Duch, PhD
The Chatham Institute
Chatham, NJ

Dr. Duch has nothing to disclose.

Faculty and Disclosures

Paul P. Doghramji, MD, FAAFP
Collegeville Family Practice
Collegeville, PA

Dr. Doghramji is a member of the speaker’s bureau for Cephalon, Inc., Pfizer, Inc., sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. He serves on the advisory board for Pfizer, sanofi-aventis, and Takeda. Dr. Doghramji is a consultant to sanofi-aventis and Takeda.

David N. Neubauer, MD (Chair)
Johns Hopkins Sleep Disorders Center
Baltimore, MD

Dr. Neubauer is a member of the speaker’s bureau for sanofi-aventis U.S. and Takeda Pharmaceuticals North America, Inc. He serves on the advisory board for Neurocrine Biosciences, Inc., sanofi-aventis, and Takeda.

Review Committee Disclosure

In accordance with our policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.

Unlabeled Use Declaration:

During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Listen to Podcast

When finished, click here to take the Post-test

Take the post-test to receive your CME certificate